{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:06:51Z","timestamp":1758845211447,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing medical award foundation","award":["YXJL-2024-0387-0085"],"award-info":[{"award-number":["YXJL-2024-0387-0085"]}]},{"name":"Beijing Life Oasis Public Service Center","award":["P119-003"],"award-info":[{"award-number":["P119-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04438-4","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T06:13:10Z","timestamp":1758780790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Efgartigimod treatment for acute myasthenia gravis exacerbation with retroperitoneal mass: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Jinyi","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalam","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peicai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"4438_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Longo DL. Myasthenia Gravis. N Engl J Med. 2016;375:2570\u201381. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"issue":"23","key":"4438_CR2","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia Gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"3","key":"4438_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous Immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52(3):629\u201332.","journal-title":"Neurology"},{"key":"4438_CR4","doi-asserted-by":"publisher","unstructured":"Neumann B, et al. Myasthenic crisis demanding mechanical ventilation. Neurology. 2020;94. https:\/\/doi.org\/10.1212\/wnl.0000000000008688.","DOI":"10.1212\/wnl.0000000000008688"},{"key":"4438_CR5","doi-asserted-by":"publisher","unstructured":"Wang Y, et al. Plasma exchange versus intravenous Immunoglobulin in achr subtype myasthenic crisis: A prospective cohort study. Clin Immunol. 2022;241. https:\/\/doi.org\/10.1016\/j.clim.2022.109058.","DOI":"10.1016\/j.clim.2022.109058"},{"key":"4438_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68:8\u201319. https:\/\/doi.org\/10.1002\/mus.27832.","journal-title":"Muscle Nerve"},{"key":"4438_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/wnl.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, et al. International consensus guidance for management of myasthenia Gravis. Neurology. 2021;96:114\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000011124.","journal-title":"Neurology"},{"issue":"4","key":"4438_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1046\/j.1526-0968.2000.004004291.x","volume":"4","author":"HC Chiu","year":"2000","unstructured":"Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia Gravis. Ther Apher. 2000;4(4):291\u20135.","journal-title":"Ther Apher"},{"issue":"11","key":"4438_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"MC Dalakas","year":"1999","unstructured":"Dalakas MC. Intravenous Immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22(11):1479\u201397.","journal-title":"Muscle Nerve"},{"key":"4438_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/00207454.2017.1366905","volume":"128","author":"Y Li","year":"2017","unstructured":"Li Y, et al. Clinical outcome and predictive factors of postoperative myasthenic crisis in 173 thymomatous myasthenia Gravis patients. Int J Neurosci. 2017;128:103\u20139. https:\/\/doi.org\/10.1080\/00207454.2017.1366905.","journal-title":"Int J Neurosci"},{"key":"4438_CR11","doi-asserted-by":"publisher","unstructured":"Chen K, Li Y, Yang H. Poor responses and adverse outcomes of myasthenia Gravis after thymectomy: predicting factors and immunological implications. J Autoimmun. 2022;132. https:\/\/doi.org\/10.1016\/j.jaut.2022.102895.","DOI":"10.1016\/j.jaut.2022.102895"},{"key":"4438_CR12","doi-asserted-by":"publisher","unstructured":"Gamez J, et al. Intravenous Immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia Gravis. Ther Adv Neurol Disord. 2019;12. https:\/\/doi.org\/10.1177\/1756286419864497.","DOI":"10.1177\/1756286419864497"},{"key":"4438_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, et al. Safety, efficacy, and tolerability of Efgartigimod in patients with generalised myasthenia Gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526\u201336. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"4438_CR14","doi-asserted-by":"publisher","unstructured":"Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia Gravis. Front Neurol. 2023;14. https:\/\/doi.org\/10.3389\/fneur.2023.1229112.","DOI":"10.3389\/fneur.2023.1229112"},{"key":"4438_CR15","first-page":"127","volume":"18","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R, Efgartigimod. A First-in-class investigational antibody fragment for the treatment of generalized myasthenia Gravis. US Neurol. 2022;18:127.","journal-title":"US Neurol"},{"key":"4438_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.04.014","author":"S Wang","year":"2025","unstructured":"Wang S, et al. Perioperative safety and efficacy of Efgartigimod for thymoma associated myasthenia gravis: A prospective, multicenter, phase II clinical trial. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.04.014.","journal-title":"J Thorac Oncol"},{"key":"4438_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","volume":"271","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, et al. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol. 2024;271:254\u201362. https:\/\/doi.org\/10.1007\/s00415-023-11970-1.","journal-title":"J Neurol"},{"key":"4438_CR18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","volume":"23","author":"JA Allen","year":"2024","unstructured":"Allen JA, et al. Safety, tolerability, and efficacy of subcutaneous Efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024;23:1013\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(24)00309-0.","journal-title":"Lancet Neurol"},{"key":"4438_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70051","author":"AA Habib","year":"2025","unstructured":"Habib AA, et al. ADAPT NXT: fixed cycles or Every-Other\u2010Week IV Efgartigimod in generalized myasthenia Gravis. Ann Clin Transl Neurol. 2025. https:\/\/doi.org\/10.1002\/acn3.70051.","journal-title":"Ann Clin Transl Neurol"},{"key":"4438_CR20","doi-asserted-by":"publisher","unstructured":"Huang Y, et al. Patients with myasthenia Gravis with acute onset of dyspnea: predictors of progression to myasthenic crisis and prognosis. Front Neurol. 2021;12. https:\/\/doi.org\/10.3389\/fneur.2021.767961.","DOI":"10.3389\/fneur.2021.767961"},{"key":"4438_CR21","doi-asserted-by":"publisher","unstructured":"Nelke C, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia Gravis patients. J Neuroinflamm. 2022;19. https:\/\/doi.org\/10.1186\/s12974-022-02448-4.","DOI":"10.1186\/s12974-022-02448-4"},{"key":"4438_CR22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, et al. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11:2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"key":"4438_CR23","doi-asserted-by":"publisher","unstructured":"Ma J, et al. Efgartigimod versus intravenous Immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep. 2024;14. https:\/\/doi.org\/10.1038\/s41598-024-79918-7.","DOI":"10.1038\/s41598-024-79918-7"},{"key":"4438_CR24","doi-asserted-by":"publisher","unstructured":"Hong Y, et al. Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series. J Neuroimmunol. 2024;395. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578431.","DOI":"10.1016\/j.jneuroim.2024.578431"},{"key":"4438_CR25","doi-asserted-by":"publisher","unstructured":"Song J, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503.","DOI":"10.3389\/fimmu.2024.1418503"},{"key":"4438_CR26","doi-asserted-by":"publisher","unstructured":"Derfuss T, et al. Outcomes after major surgery in patients with myasthenia gravis: A nationwide matched cohort study. PLoS ONE. 2017;12. https:\/\/doi.org\/10.1371\/journal.pone.0180433.","DOI":"10.1371\/journal.pone.0180433"},{"key":"4438_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bjae.2021.07.001","volume":"21","author":"P Daum","year":"2021","unstructured":"Daum P, Smelt J, Ibrahim IR. Perioperative management of myasthenia Gravis. BJA Educ. 2021;21:414\u20139. https:\/\/doi.org\/10.1016\/j.bjae.2021.07.001.","journal-title":"BJA Educ"},{"issue":"6","key":"4438_CR28","first-page":"485","volume":"88","author":"S Collins","year":"2020","unstructured":"Collins S, Roberts H, Hewer I. Anesthesia and perioperative considerations for patients with myasthenia Gravis. AANA J. 2020;88(6):485\u201391.","journal-title":"AANA J"},{"key":"4438_CR29","doi-asserted-by":"publisher","unstructured":"Shelly S. Case report: successful perioperative intervention with Efgartigimod in a patient in myasthenic crisis. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1524200.","DOI":"10.3389\/fimmu.2025.1524200"},{"issue":"4","key":"4438_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","volume":"9","author":"B Castleman","year":"1956","unstructured":"Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822\u201330.","journal-title":"Cancer"},{"issue":"2","key":"4438_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0046-8177(85)80065-4","volume":"16","author":"DD Weisenburger","year":"1985","unstructured":"Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol. 1985;16(2):162\u201372.","journal-title":"Hum Pathol"},{"issue":"4","key":"4438_CR32","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/rheumatology\/keac481","volume":"62","author":"A Gonz\u00e1lez Garc\u00eda","year":"2023","unstructured":"Gonz\u00e1lez Garc\u00eda A, Fern\u00e1ndez-Mart\u00edn J, Robles Marhuenda \u00c1. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford). 2023;62(4):1426\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"4438_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/BOR.0b013e32834db525","volume":"24","author":"TW Muskardin","year":"2012","unstructured":"Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol. 2012;24:76\u201383. https:\/\/doi.org\/10.1097\/BOR.0b013e32834db525.","journal-title":"Curr Opin Rheumatol"},{"key":"4438_CR34","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00432-020-03494-2","volume":"147","author":"D-P Sun","year":"2021","unstructured":"Sun D-P, et al. Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. J Cancer Res Clin Oncol. 2021;147:2107\u201315. https:\/\/doi.org\/10.1007\/s00432-020-03494-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"4438_CR35","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"K Yoshizaki","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, et al. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in castleman\u2019s disease. Blood. 1989;74(4):1360\u20137.","journal-title":"Blood"},{"key":"4438_CR36","doi-asserted-by":"publisher","unstructured":"Uzawa A, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia Gravis. J Neuroimmunol. 2021;358. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577634.","DOI":"10.1016\/j.jneuroim.2021.577634"},{"key":"4438_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.rceng.2016.01.001","volume":"216","author":"A Gonz\u00e1lez Garc\u00eda","year":"2016","unstructured":"Gonz\u00e1lez Garc\u00eda A, Moreno Cobo M\u00c1. Patier de La pe\u00f1a, J. L. Current diagnosis and treatment of castleman\u2019s disease. Revista Cl\u00ednica Espa\u00f1ola (English Edition). 2016;216:146\u201356. https:\/\/doi.org\/10.1016\/j.rceng.2016.01.001.","journal-title":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)"},{"key":"4438_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.blre.2017.11.005","volume":"32","author":"M Haap","year":"2018","unstructured":"Haap M, Wiefels J, Horger M, Hoyer A, M\u00fcssig K. Clinical, laboratory and imaging findings in castleman\u2019s disease \u2013 The subtype decides. Blood Rev. 2018;32:225\u201334. https:\/\/doi.org\/10.1016\/j.blre.2017.11.005.","journal-title":"Blood Rev"},{"key":"4438_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2174\/1573409915666190902142524","volume":"16","author":"A Aher","year":"2020","unstructured":"Aher A, et al. In Silico insights on IL-6: A potential target for multicentric Castleman disease. Curr Comput-Aided Drug Design. 2020;16:641\u201353. https:\/\/doi.org\/10.2174\/1573409915666190902142524.","journal-title":"Curr Comput-Aided Drug Design"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04438-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T06:13:11Z","timestamp":1758780791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04438-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4438"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04438-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this study was obtained from the the patient\u2019s family. Our institution does not require ethical approval for reporting individual cases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participant member gave written informed consent for their personal or clinical details along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}